Please assess the completion status of the following clinical trial:

Trial Title: A Study of JNJ-70033093 (BMS-986177) Versus Subcutaneous Enoxaparin in Participants Undergoing Elective Total Knee Replacement Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 8.0

Eligibility Criteria:
Inclusion Criteria:~* Medically stable and appropriate for anticoagulant prophylaxis as determined by the investigator on the basis of physical examination, medical history, and vital signs performed as part of screening for elective total knee replacement (TKR) surgery~* Medically stable and appropriate for anticoagulant prophylaxis on the basis of clinical laboratory tests performed as part of local standard-of-care as part of screening for elective TKR surgery~* Has plans to undergo an elective primary unilateral TKR surgery~* A woman must be- a) Not of childbearing potential; b) Of childbearing potential and practicing a highly effective method of contraception (failure rate of less than \[\<\]1 percent \[%\] per year when used consistently and correctly) and agrees to remain on a highly effective method for the duration of study drug with JNJ-70033093 plus 5 half-lives of study drug plus 30 days (duration of ovulatory cycle) for a total of 34 days after the completion of treatment, pregnancy testing (serum or urine) prior to the first dose of study drug~* Willing and able to adhere to the lifestyle restrictions specified in this protocol~Exclusion Criteria:~* History of any condition for which the use of low molecular-weight heparin (LMWH) is not recommended in the opinion of the investigator (for example, previous allergic reaction, creatinine clearance \<30 milliliter per minute \[mL/minute\])~* History of severe hepatic impairment~* Planned bilateral revision or unicompartmental procedure~* Unable to undergo venography (for example, due to contrast agent allergy, poor venous access, or impaired renal function that would increase the risk of contrast-induced nephropathy~* Known previous pulmonary embolism (PE) or deep vein thrombosis (DVT) in either lower extremity

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group A: JNJ-70033093 25 mg + Placebo BID (Type: EXPERIMENTAL): Participants will receive JNJ-70033093 25 milligram (mg) (1\*25 mg capsule) and 1 placebo capsule twice daily (BID), orally for 10 to 14 postoperative days.
- Group B: JNJ-70033093 50 mg BID (Type: EXPERIMENTAL): Participants will receive JNJ-70033093 50 mg (2\*25 mg capsules) BID orally for 10 to 14 postoperative days.
- Group C: JNJ-70033093 100 mg + Placebo BID (Type: EXPERIMENTAL): Participants will receive JNJ-70033093 100 mg (1\*100 mg capsule) and 1 placebo capsule BID orally for 10 to 14 postoperative days.
- Group D: JNJ-70033093 200 mg BID (Type: EXPERIMENTAL): Participants will receive JNJ-70033093 200 mg (2\*100 mg capsules) BID orally for 10 to 14 postoperative days.
- Group E: JNJ-70033093 25 mg Once Daily + Placebo (Type: EXPERIMENTAL): Participants will receive JNJ-70033093 25 mg (1\*25 mg capsule) once daily and 1 placebo capsule in the morning and 2 placebo capsules in the evening, orally for 10 to 14 postoperative days.
- Group F: JNJ-70033093 200 mg Once Daily + Placebo (Type: EXPERIMENTAL): Participants will receive JNJ-70033093 200 mg (2\*100 mg capsules in the morning) once daily and 2 placebo capsules in the evening, orally for 10 to 14 postoperative days.
- Group G: JNJ-70033093 50 mg once daily + Placebo (Type: EXPERIMENTAL): Participants will receive JNJ-70033093 50 mg (2\*25 mg capsules in the morning) once daily and 2 placebo capsules in the evening, orally for 10 to 14 postoperative days.
- Group I: Enoxaparin 40 mg Once Daily (Type: ACTIVE_COMPARATOR): Participants will receive enoxaparin 40 mg once daily subcutaneously for 10 to 14 postoperative days.

Based on this trial design, predict the completion outcome and termination type (if applicable).